Sven Gogov

1.6k total citations
25 papers, 804 citations indexed

About

Sven Gogov is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sven Gogov has authored 25 papers receiving a total of 804 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Sven Gogov's work include Cancer Immunotherapy and Biomarkers (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Hedgehog Signaling Pathway Studies (4 papers). Sven Gogov is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Hedgehog Signaling Pathway Studies (4 papers). Sven Gogov collaborates with scholars based in Switzerland, United States and Canada. Sven Gogov's co-authors include Shabbir M.H. Alibhai, Michael Thomas, Peter Langmuir, Glenwood Goss, Jacqui Rowbottom, Chun‐Ming Tsai, Robert C. Whorf, David Ferry, Ronald B. Natale and Fabrice Barlési and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Diabetes Care.

In The Last Decade

Sven Gogov

23 papers receiving 779 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sven Gogov Switzerland 12 409 351 294 145 86 25 804
Yu Dong China 14 389 1.0× 455 1.3× 213 0.7× 150 1.0× 106 1.2× 68 913
Raimondo Di Liello Italy 13 228 0.6× 357 1.0× 265 0.9× 113 0.8× 87 1.0× 33 738
Hideyo Miyazaki Japan 14 318 0.8× 299 0.9× 408 1.4× 116 0.8× 38 0.4× 38 933
Tatsuo Morita Japan 18 344 0.8× 394 1.1× 328 1.1× 124 0.9× 171 2.0× 100 1.1k
Chi‐Young Jeong South Korea 20 412 1.0× 393 1.1× 212 0.7× 147 1.0× 57 0.7× 58 1.1k
Hiroshi Wakui Japan 15 345 0.8× 412 1.2× 233 0.8× 74 0.5× 103 1.2× 42 816
Fadi Farhat Lebanon 17 234 0.6× 196 0.6× 188 0.6× 82 0.6× 65 0.8× 55 684
Yoshiaki Sugiura Japan 14 286 0.7× 373 1.1× 380 1.3× 209 1.4× 37 0.4× 41 1.0k
Chiao‐En Wu Taiwan 17 280 0.7× 499 1.4× 289 1.0× 154 1.1× 61 0.7× 92 933
Masayuki Hagiwara Japan 17 265 0.6× 299 0.9× 311 1.1× 126 0.9× 65 0.8× 58 819

Countries citing papers authored by Sven Gogov

Since Specialization
Citations

This map shows the geographic impact of Sven Gogov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Gogov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Gogov more than expected).

Fields of papers citing papers by Sven Gogov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Gogov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Gogov. The network helps show where Sven Gogov may publish in the future.

Co-authorship network of co-authors of Sven Gogov

This figure shows the co-authorship network connecting the top 25 collaborators of Sven Gogov. A scholar is included among the top collaborators of Sven Gogov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Gogov. Sven Gogov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
D’Alise, Anna Morena, Guido Leoni, Gabriella Cotugno, et al.. (2024). Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses. Clinical Cancer Research. 30(11). 2412–2423. 23 indexed citations
2.
Vilar, Eduardo, Jason Willis, Michael J. Hall, et al.. (2024). 638 Nous-209 vaccine induces shared neoantigen immunogenicity for cancer interception in healthy lynch syndrome carriers: results from phase Ib/II trial. Regular and Young Investigator Award Abstracts. A732–A732. 1 indexed citations
3.
Overman, Michael J., Joan Maurel, Paul E. Oberstein, et al.. (2023). Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer.. Journal of Clinical Oncology. 41(16_suppl). e14665–e14665. 10 indexed citations
4.
Bechter, Oliver, Anna Morena D’Alise, Guido Leoni, et al.. (2023). Abstract LB196: NOUS-PEV, a personalized cancer immunotherapy targeting neoantigens, induces long lasting, tumor infiltrating memory T cells. Cancer Research. 83(8_Supplement). LB196–LB196. 5 indexed citations
5.
Bechter, Oliver, Juan Martín-Liberal, Anna Morena D’Alise, et al.. (2022). 706 NOUS-PEV, a novel personalized viral-based prime/boost cancer immunotherapy targeting patient-specific neoantigens: interim results from the first subjects in the phase 1b study. Regular and Young Investigator Award Abstracts. A739–A739. 4 indexed citations
6.
Naing, Aung, Todd M. Bauer, K. Papadopoulos, et al.. (2019). Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours. Annals of Oncology. 30. v160–v160. 34 indexed citations
7.
Macaulay, Valentine M., Mark R. Middleton, Sabine Eckhardt, et al.. (2016). Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(12). 2897–2907. 49 indexed citations
8.
Goel, Varun, Eunju Hurh, Andrew M. Stein, et al.. (2016). Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 77(4). 745–755. 33 indexed citations
9.
Dummer, Reinhard, Vernon K. Sondak, James M. Grichnik, et al.. (2015). Composite assessment of treatment response in patients (pts) with locally advanced basal cell carcinoma (laBCC): Sonidegib efficacy using two sets of response criteria.. Journal of Clinical Oncology. 33(15_suppl). e20055–e20055. 1 indexed citations
10.
Migden, Michael R., Alexander Guminski, Ralf Gutzmer, et al.. (2014). Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC). Journal of Clinical Oncology. 32(15_suppl). 9009a–9009a. 11 indexed citations
11.
Besse, Benjamin, Natasha B. Leighl, Jaafar Bennouna, et al.. (2013). Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer. Annals of Oncology. 25(2). 409–415. 53 indexed citations
12.
13.
Eberhardt, Wilfried, Paul Mitchell, Joan H. Schiller, et al.. (2013). Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer. Investigational New Drugs. 32(1). 123–134. 4 indexed citations
14.
15.
Motzer, Robert J., Carlos H. Barrios, Tae Min Kim, et al.. (2013). Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 31(15_suppl). 4504–4504. 54 indexed citations
16.
17.
Natale, Ronald B., Sumitra Thongprasert, F. Anthony Greco, et al.. (2011). Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(8). 1059–1066. 244 indexed citations
18.
Alibhai, Shabbir M.H., et al.. (2006). Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review. Critical Reviews in Oncology/Hematology. 60(3). 201–215. 142 indexed citations
19.
Alibhai, Shabbir M.H. & Sven Gogov. (2005). Radical prostatectomy for early prostate cancer improves long term survival. Cancer Treatment Reviews. 31(8). 640–643. 4 indexed citations
20.
Zinman, Lorne, et al.. (2004). Low-Intensity Laser Therapy for Painful Symptoms of Diabetic Sensorimotor Polyneuropathy. Diabetes Care. 27(4). 921–924. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yu Dong Breakdown of academic impact, for papers by Raimondo Di Liello Breakdown of academic impact, for papers by Hideyo Miyazaki Breakdown of academic impact, for papers by Tatsuo Morita Breakdown of academic impact, for papers by Chi‐Young Jeong Breakdown of academic impact, for papers by Hiroshi Wakui Breakdown of academic impact, for papers by Fadi Farhat Breakdown of academic impact, for papers by Yoshiaki Sugiura Breakdown of academic impact, for papers by Chiao‐En Wu Breakdown of academic impact, for papers by Masayuki Hagiwara
Rankless by CCL
2026